Global In vitro drug discovery Market Research Report
show more| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
 |
Cell based assays Cell based assays and Next Generation Sequencer (NGS), Metabolomics, |
Upcoming |
|
|
Payment Link- High throughput screening The global High Throughput Screening market was valued at $14.38 billion in 2013 and is expected to reach $20.58 billion by 2018, growing at a CAGR of 7.4% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland). |
Upcoming |
|
|
High content analysis/Screening The global High Content Screening market was valued at $380.31 million in 2013 and is expected to reach $646.59 million by 2018, growing at a CAGR of 11.2% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments, consumables, software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), among others |
Upcoming |
|
|
North American High Content analysis/Screening The North American High Content Screening market was valued at $161.8 million in 2013 and is expected to reach $280.7 million by 2018, growing at a CAGR of 11.7% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
|
|
European High content analysis/Screening The European High Content Screening market was valued at $124.29 million in 2013 and is expected to reach $207.9 million by 2018, growing at a CAGR of 10.6% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
|
|
Asian High content analysis/Screening The Asian High Content Screening market was valued at $55.75 million in 2013 and is expected to reach $101.74 million by 2018, growing at a CAGR of 12.8% from 2013 to 2018.High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
|
|
North American High throughput screening The North American High Throughput Screening market was valued at $6454.3 million in 2013 and is expected to reach $9046.8 million by 2018, growing at a CAGR of 7.0% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland). |
Upcoming |
|
|
European High throughput screening The European High Throughput Screening market was valued at $3794.7 million in 2013 and is expected to reach $5194.3 million by 2018, growing at a CAGR of 6.5% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland). |
Upcoming |
|
|
Asian High throughput screening The Asian High Throughput Screening market was valued at $2547.3 million in 2013 and is expected to reach $3931.2 million by 2018, growing at a CAGR of 9.1% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland). |
Upcoming |
9 reports |
Show
In vitro drug discovery
